Patient and nursing experience of flash glucose monitoring following kidney transplantation

Abstract

AbstractFlash glucose monitoring (FGM) is increasingly used for blood glucose assessment due to ease of use and is now subsidized in Australia for blood glucose measurement for patients with Type 1 Diabetes Mellitus. Dysglycaemia is common following kidney transplantation and is associated with worse outcomes and there are data to support the use of FGM post‐transplant to better detect and manage changes in blood glucose levels. There is, however, no data on patient or staff perceptions of FGM, or resource implications in this setting. We prospectively evaluated patients and nursing staff experiences of FGM compared to traditional capillary glucose measurement in the immediate post‐transplant setting, along with resource utilization, cost of testing, staff time taken to test and accuracy. Twenty‐one kidney transplant recipients had a FGM sensor applied in the post‐operative period and results compared to capillary blood glucose monitoring (CBGM) measured at least four times a day. Six‐hundred‐fifty‐six glucose measurements were obtained, median per patient of 30 readings (IQR 10). Pearson's correlation between FGM and CBGM readings is 0.95 (p < .001). FGM readings were lower than CBGM by an average of 1.2 mmol/L (SD 0.7). Using a 5‐point preference questionnaire (with ratings varying from strongly disagree‐strongly agree), both patients and nurses were highly satisfied with the usability and convenience of FGM, with all preferring FGM over CBGM. Average time to perform FGM was 3.6 s versus 64 s for CBGM. In average, cost of FGM was $58 less than traditional testing per patient. FGM is an accurate, convenient and cost‐effective tool that may support optimal management of glycaemic control in the post‐transplant period.